Bicara Therapeutics Inc. Cash and Restricted Cash
Bicara Therapeutics Inc. (BCAX) had Cash and Restricted Cash of $96.60 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $96.60M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $323.46M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $96.69M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $171.67M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $96.60M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $323.46M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $96.69M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $171.67M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $436.61M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $462.06M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $489.71M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $520.76M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $203.85M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $216.05M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $230.44M 10-K · filed 2026-03-30 |
| 2023-09-30 | $44.21M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $4.16M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |